Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Bien

Otology & Neurotology Oklahoma City, OK Medical Doctor

NPI 1881734614 CMS profile 39673

825 Ne 10Th St, Oklahoma City, OK 73104

Open in the dashboard

General payments

$15,071

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Bien of Oklahoma City, OK is reported in the CMS Open Payments database as having received $15,071 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $639 7
2024 General $11,814 28
2023 General $924 9
2022 General $567 9
2021 General $343 10
2020 General $40 1
2019 General $743 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Bien
  • Otology & Neurotology median
  • Middle half of Otology & Neurotology
  • National median

In program year 2025, general payments to Alexander Bien were reported at $639. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.

Show as a table
Year Alexander Bien Otology & Neurotology median Middle half National median
2019 $743 $349 $117–$1,358 $163
2020 $40 $118 $58–$325 $114
2021 $343 $186 $81–$600 $132
2022 $567 $290 $129–$938 $149
2023 $924 $335 $119–$978 $160
2024 $11,814 $399 $138–$1,384 $164
2025 $639 $411 $148–$1,608 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $11,303 22 payments
  2. MED-EL Corporation $1,500 19 payments
  3. Advanced Bionics, LLC $580 15 payments
  4. Grace Medical, Inc. $556 3 payments
  5. Cochlear Americas $393 11 payments
  6. AxoGen $310 3 payments
  7. Stryker Corporation $208 3 payments
  8. GlaxoSmithKline, LLC. $125 1 payment
  9. Novartis Pharmaceuticals Corporation $53 2 payments
  10. SpringWorks Therapeutics, Inc. $22 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,640 1 payment
  2. Food and Beverage $4,596 71 payments
  3. Travel and Lodging $1,835 9 payments
Products named General payments · program years 2019–2025
  1. MIDAS REX $10,777 17 payments
  2. BCI 602 Kit $1,212 14 payments
  3. Mi1250 SYNCHRONY 2 FLEXsoft $1,148 13 payments
  4. ADHEAR Professional Kit $489 6 payments
  5. HiResolution Bionic Ear System $372 7 payments
  6. STEALTHSTATION S8 PLATFORM $322 3 payments
  7. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $261 7 payments
  8. MED-EL Maestro Cochlear Implant System $189 3 payments
  9. NICO MYRIAD SPECTRA $172 1 payment
  10. Avance Nerve Graft $164 2 payments
  11. Other $2,309 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

86

Median for Otolaryngology: 297

Drug cost

$3,858

Median for Otolaryngology: $6,314

Branded share of claims

27.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 24 $2,594
Ofloxacin Generic 28 $651
Fluticasone Propionate Generic 23 $337
Azelastine Hcl Generic 11 $275

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$58,315

Medicare's payments for the services billed

Medicare patients

196

Average age 71

Services billed

471

103 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 34%
Ischemic heart disease 30%
Depression 25%
Chronic kidney disease 22%
Heart failure 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otology & Neurotology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record